ArticleJAMA network open2025
Atopic Disease Development in Offspring Conceived via Assisted Reproductive Technology.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: As assisted reproductive technology (ART) becomes increasingly prevalent, concerns regarding the potential short-term and long-term health outcomes of children conceived through these methods have emerged. Objective: To investigate whether conception via ART is associated with a risk of atopic disease development in offspring. Design, Setting, and Participants: This retrospective, population-based cohort study was conducted using data obtained from Taiwan's National Health Insurance Research Database, Assisted Reproduction Database, and Maternal and Child Health Database. Children conceived via ART and born between January 1, 2004, and December 31, 2014, were identified as the exposure group. A control group of children conceived naturally was selected using 1:4 matching based on maternal age, neonatal sex, and birth month. Data analysis was performed from December 1, 2023, to November 1, 2025. Exposure: Conception via ART or naturally. Main Outcomes and Measures: The primary outcome was development of atopic disease. Both groups were followed up until December 31, 2020. Cox proportional hazards regression models were used to adjust potential confounders. Results: A total of 69 785 children (13 957 in the ART group and 55 828 in the control group) were included in this study, with follow-up beginning at birth. The study population was 47.5% female and 52.5% male. For the ART and control groups, the mean (SD) follow-up duration was 7.99 (4.22) and 8.41 (4.18) years for asthma, 5.79 (4.12) and 6.34 (4.28) years for allergic rhinitis, and 7.34 (5.13) and 7.62 (5.14) years for atopic dermatitis, respectively. After adjusting for potential confounders, the ART group exhibited a higher likelihood of developing asthma (adjusted hazard ratio [AHR], 1.13 [95% CI, 1.09-1.18]), allergic rhinitis (AHR, 1.15 [95% CI, 1.12-1.18]), or atopic dermatitis (AHR, 1.08 [95% CI, 1.05-1.12]) (all P < .001) compared with the control group. Subgroup analysis revealed that children conceived with fresh embryos faced a greater risk of developing allergic rhinitis compared with those conceived with frozen embryos (AHR, 1.12 [95% CI, 1.06-1.19]; P < .001). Conclusions and Relevance: The findings of this cohort study suggest that children conceived via ART had a higher risk of developing asthma, allergic rhinitis, or atopic dermatitis. These findings underscore the importance of long-term follow-up for offspring conceived via ART and further investigation into the underlying biological mechanisms by which ART may contribute to atopic disease development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.